Clinical and prognostic features of MMP-2 and VEGF in AEG patients

Qing-Kang Zheng, Qing Yin, Nan Zhang, Zhi-Gang Sun*

Abstract: Adenocarcinoma of the esophagogastric junction (AEG) has been increased in recent years and has become a worldwide problem that seriously affects human health. The purpose of the study is to investigate the clinical and prognostic characteristics of the matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) expression in AEG patients. A total of 69 patients were enrolled in this study. The result showed that the high expression of MMP-2 was significantly associated with tumor differentiation ($P < 0.05$) and depth of invasion ($pT$, $P < 0.05$). The high expression of VEGF was significantly associated with pT ($P < 0.05$) and lymph node metastasis ($pN$, $P < 0.05$). There was a positive correlation between MMP-2 and VEGF expression ($P < 0.01$). The 5-year survival rate for the 69 AEG patients was 40.6% and it was significantly associated with tumor differentiation ($P < 0.05$), pN ($P < 0.01$), pTNM stage ($P < 0.01$), MMP-2 expression ($P < 0.05$), and VEGF expression ($P < 0.05$). Cox multivariate regression demonstrated that tumor differentiation and pN were independent factors for the 5-year survival rate. Our study showed that MMP-2 and VEGF could work synergistically in AEG development.

Keywords: adenocarcinoma of the esophagogastric junction, MMP-2, VEGF, immunohistochemistry

1 Introduction

Adenocarcinoma of the esophagogastric junction (AEG) incidents have increased in recent years and become a worldwide problem that seriously affects human health \cite{1,2}. AEG is defined as the malignant tumor whose center is within 5 cm of the proximal and distal ends of the esophagogastric junction (EGJ). It includes proximal gastric cancer, cardiac cancer, and distal esophageal adenocarcinoma \cite{3}. Due to its particular anatomical location, the pathological type of AEG is adenocarcinoma, while the epidemiological characteristics and clinical symptoms of AEG are consistent with esophageal squamous cell carcinoma \cite{4,5}. At present, more and more scholars regard AEG as an independent malignant tumor that is different from gastric cancer and esophageal adenocarcinoma \cite{6,7}. Because of the high recurrences rates, the prognosis of AEG patients remains poor even after the curative surgery treatment \cite{8,9}. The TNM staging system lacks sufficient implied rate, because significantly different survival rate is often observed in the same TNM stage. Therefore, it is meaningful to combine some biomarkers with TNM staging to distinguish AEG patients with poor prognosis.

Matrix metalloproteinases (MMPs), a family of extracellular zinc-dependent endopeptidases \cite{10}, play pivotal roles in tumor infiltration, invasion, and angiogenesis \cite{11,12}. Among the MMPs, MMP-2 acts as a key enzyme that could be related to tumor metastasis and physiologic functions \cite{13}. Vascular endothelial growth factor (VEGF) is an angiogenic factor produced by cancer cells and could stimulate the growth of endothelial cells \cite{12}. It could promote endothelial cells proliferation and migration, enhance the permeability of blood vessels, promote stromal proteolysis, and reduce endothelial cell apoptosis \cite{13}. It has been reported that VEGF could induce multiple proteases expression including MMPs which leads to extracellular matrix around vessels \cite{14}. The purpose of the study is to investigate the clinic and prognostic characteristics of MMP-2 and VEGF expression in postoperative AEG patients using both univariate and
multivariate analysis, and the MMP-2 and VEGF expression was detected using immunohistochemistry (IHC) at protein level.

2 Materials and methods

2.1 Patients

Total of 69 AEG cases were enrolled into the study conducted at the Department of Thoracic Surgery and General Surgery, Jinan Central Hospital between January 2010 and May 2013. The inclusion criteria were as follows: (1) patients underwent surgery and affirmed AEG by pathology; (2) the TNM staging system of AEG was based on the International Union Against Cancer (2009) guideline; (3) the subjects had no preoperative chemotherapy or radiotherapy treatment; (4) the cases had no seriously surgical contraindications that could affect prognosis. (5) The follow-up data of the cases were complete. The clinic data of the AEG patients were shown in Table 1. This research was approved by the Ethics Committee of Jinan Central Hospital and was in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 2000. And all the patients consented to the study.

2.2 Immunohistochemistry

All the AEG specimens were obtained from the 69 cases. The tissue specimens were fixed in 10% neutral buffered formalin and processed routinely. MMP-2 and VEGF were detected by the streptavidin-peroxidase (SP) method using the same paraffin-embedded tissue samples, which were cut into 4-mm-thick slices. The primary antibody was applied using mouse antihuman monoclonal MMP-2 antibodies (1:150, Catalogue TA806846, Zhongshan Jinqiao Biotechnology, Beijing, P. R. China) or mouse antihuman monoclonal VEGF antibodies (1:100, Catalogue ZM-0265, Zhongshan Jinqiao Biotechnology, Beijing, P. R. China). The IHC protocols were described previously [15–17].

Table 1: Correlation between MMP-2 and VEGF expression and clinicopathological features of the patients with adenocarcinoma of the esophagogastric junction

| Clinical features          | Patients | MMP-2 | VEGF |
|---------------------------|----------|-------|------|
|                           |          | Low   | High | P     | Low | High | P     |
|                           | 69       | 21    | 48   |       | 20  | 49   |       |
| Gender                    |          |       |      |       |     |      |       |
| Male                      | 50       | 14    | 36   | *0.561| 16  | 34   | *0.554|
| Female                    | 19       | 7     | 12   |       | 4   | 15   |       |
| Age, year                 |          |       |      |       |     |      |       |
| <60                       | 26       | 7     | 19   | *0.788| 10  | 24   | 0.234 |
| ≥60                       | 43       | 14    | 29   |       | 17  | 22   |       |
| Differentiation           |          |       |      |       |     |      |       |
| Well + Moderately         | 32       | 14    | 18   | *0.036| 11  | 21   | *0.430|
| Poorly                    | 37       | 7     | 30   |       | 9   | 28   |       |
| pT                        |          |       |      |       |     |      |       |
| pT1 + pT2                 | 34       | 15    | 19   | *0.019| 14  | 20   | *0.036|
| pT3 + pT4                 | 35       | 6     | 29   |       | 6   | 29   |       |
| pN                        |          |       |      |       |     |      |       |
| –                         | 28       | 11    | 17   | *0.286| 14  | 14   | *0.003|
| +                         | 41       | 10    | 31   |       | 6   | 35   |       |
| pTNM                      |          |       |      |       |     |      |       |
| pl + pl1                  | 40       | 15    | 25   | *0.187| 15  | 25   | *0.106|
| plII                      | 29       | 6     | 23   |       | 5   | 24   |       |
| VEGF                      |          |       |      |       |     |      |       |
| Low                       | 20       | 11    | 9    | **0.004| —  | —    | —     |
| High                      | 49       | 10    | 39   |       | —   | —    |       |

P: χ² test, *Fisher’s exact probability test, **Spearman’s rank correlation coefficient; pT, tumor invasion; pN, lymph node metastasis, pTNM, tumor stage; MMP-2, matrix metalloproteinases 2; VEGF, vascular endothelial growth factor.
2.3 Immunohistochemical findings evaluation

Cell counts were performed by counting 200 cells in each area of at least 5 randomly selected areas with 400× magnification using a light microscope. MMP-2 expression was mainly located in the cytoplasm and plasma membrane of the tumor cells and categorized under the following conditions: low expression, less than 50% of cells; high expression, 50% or more of cells (Figure 1) [16]. VEGF expression was mainly located in the cytoplasm of the tumor cells and was categorized as follows: staining the rate of tumor cells was scored between 0 and 4: 0 (below 5%), 1 (6–25%), 2 (26–50%), 3 (51–75%), and 4 (above 75%); staining intensity was scored between 0 and 3: 0 (negative), 1 (mildly positive), 2 (moderately positive), and 3 (strongly positive). The final score was obtained by multiplying diffusion and intensity scores. Those with final scores ≤4 were classified as low expression group and those with ≥5 as high expression group (Figure 2) [17].

2.4 Statistical analysis

Enumeration data were performed by $\chi^2$ test or Fisher’s exact probability test. The correlation between MMP-2 and VEGF expression was analyzed using Spearman’s rank correlation coefficient. Univariate analysis was performed with Kaplan–Meier survival curves. Multivariate analysis was performed by the Cox proportional hazard model. All statistical data were analyzed using SPSS (IBM SPSS, Statistics 25, USA), and $P < 0.05$ indicated a statistically significant difference.

Figure 1: Immunohistochemical staining of adenocarcinoma of the esophagogastric junction (AEG) tissue sections demonstrating Matrix metalloproteinase-2 (MMP-2) (Original magnification ×200). (a) AEG specimen with high expression of MMP-2. (b) AEG specimen with low expression of MMP-2. (c) The corresponding normal gastric tissue specimen with no MMP-2 expression (contrast). (d) The corresponding normal esophageal tissue specimen with no MMP-2 expression (contrast).
2.5 Follow-up

Overall, 32 cases had postsurgical chemotherapy, 3 cases had postsurgical radiotherapy, and 19 cases had postsurgical radiotherapy combined with chemotherapy. Patients who died of tumor were included in the prognostic analysis.

3 Results

The high expression of MMP-2 was significantly associated with tumor differentiation (Well + Moderately 56.3% vs Poorly 81.1%; \( P < 0.05 \)) and depth of invasion (pT; pT1 + pT2 55.9% vs pT3 + pT4 82.9%; \( P < 0.05 \)). No statistically significant correlations with gender, age, pN, and pTNM stage were demonstrated for MMP-2 (\( P > 0.05 \)). The high expression of VEGF was significantly associated with pT (pT1 + pT2 58.9% vs pT3 + pT4 82.9%; \( P < 0.05 \)) and pN (pN – 50.0% vs pN + 85.4%; \( P < 0.05 \)). No statistically significant correlations with gender, age, tumor differentiation, and pTNM stage were demonstrated for VEGF (\( P > 0.05 \)). There was a positive correlation between MMP-2 and VEGF expression (\( P < 0.01 \)) (Table 1).

The 5-year survival rate for all the 69 AEG patients was 40.6%. A univariate analysis was conducted using the log-rank test, and the 5-year survival rate was significantly associated with differentiation (\( P < 0.05 \)), pN (\( P < 0.01 \)), pTNM stage (\( P < 0.01 \)), MMP-2 expression (\( P < 0.05 \)), and VEGF expression (\( P < 0.05 \)) (Figure 3, Table 2). The 5-year survival rate of patients with low MMP-2 expression in AEG tissues was significantly higher than those with high MMP-2 expression (61.9% vs 31.3%; \( P = 0.013 \)).
Similarly, the 5-year survival rate of patients with low VEGF expression in AEG tissues was significantly higher than those with high VEGF expression (60.0% vs 32.7%; \( P = 0.048 \)). The Cox multivariate regression result showed that both tumor differentiation and pN were independent factors for the 5-year survival rate (Table 3).

**Figure 3:** (a) The Kaplan-Meier survival curve of 69 cases of AEG patients. (b) Survival curves of AEG patients with tumor differentiation. (c) Survival curves of AEG patients with negative or positive pN. (d) Survival curves of AEG patients with different pTNM. (e) Survival curves of AEG patients with low or high expression of MMP-2 expression. (f) Survival curves of AEG patients with low or high expression of VEGF expression.
Table 2: Univariate analysis with respect to 5-year survival of the patients with adenocarcinoma of the esophagogastric junction

| Clinical features | Patients | 5-year survival (%) |
|-------------------|----------|---------------------|
|                   |          | Patients | Rate (%) | P value |
| Gender            |          |          |          |         |
| Male              | 50       | 20       | 69       | 28      | 40.0  | 0.617  |
| Female            | 19       | 8        |          |         | 11.1  |        |
| Age, year         |          |          |          |         |       | 0.223  |
| <60               | 26       | 8        |          |         |       |        |
| ≥60               | 43       | 20       |          |         |       |        |
| Differentiation   |          |          |          |         |       | 0.011  |
| Well + moderately | 32       | 17       |          |         |       |        |
| Poorly            | 37       | 11       |          |         |       |        |
| pT                |          |          |          |         |       | 0.183  |
| pT1 + pT2         | 34       | 16       |          |         |       |        |
| pT3               | 35       | 12       |          |         |       |        |
| pN                |          |          |          |         |       | 0.001  |
| −                 | 28       | 21       |          |         |       |        |
| +                 | 41       | 7        |          |         |       |        |
| pTNM              |          |          |          |         |       | 0.001  |
| pI + pII          | 40       | 23       |          |         |       |        |
| pII               | 29       | 5        |          |         |       |        |
| Chemotherapy      |          |          |          |         |       | 0.946  |
| No                | 18       | 8        |          |         |       |        |
| Yes               | 51       | 20       |          |         |       |        |
| Radiotherapy      |          |          |          |         |       | 0.896  |
| No                | 47       | 19       |          |         |       |        |
| Yes               | 22       | 9        |          |         |       |        |
| MMP-2             |          |          |          |         |       | 0.013  |
| Low               | 21       | 13       |          |         |       |        |
| High              | 48       | 15       |          |         |       |        |
| VEGF              |          |          |          |         |       | 0.048  |
| Low               | 20       | 12       |          |         |       |        |
| High              | 49       | 16       |          |         |       |        |

P, log-rank test; SCC, squamous cell carcinoma; ADC, adenocarcinoma; pT, tumor invasion; pN, lymph node metastasis, pTNM, tumor stage; MMP-2, matrix metalloproteinases 2; VEGF, vascular endothelial growth factor.

4 Discussion

Matrix metalloproteinase 2 (MMP-2), as one of the MMPs family members, has been confirmed to promote invasion and metastasis in many kinds of tumors [18,19]. Reports show that MMP-2 is highly expressed in cancers such as ovarian cancer [20], renal cell carcinoma [21], and prostate cancer [22], leading to poor survival of patients. However, the prognostic characteristics of MMP-2 expression in tumor patients remain controversial. In Pellikainen JM’s report, the high MMP-2 expression in cancer cells had no prognostic value for breast cancer patients [23].

By contrast, Shen et al. [24] had the opposite conclusion. They found that MMP-2 overexpression was a predictive factor for poor prognosis of gastric cancer. Qian et al. [25] and Liu et al. made the [26] same conclusions as Shen’s by studying non-small cell lung cancer (NSCLC) and endometrial cancer, respectively. However, little research has been done for the MMP-2 clinical features in AEG patients. Lu et al. [27] detected MMP-2 expression using IHC in tumors specimens from 120 AEG patients. They found that 51.7% of the cases had MMP-2 overexpression. However, no significant associations were found between MMP-2 and clinicopathological features in these AEG patients. Based on the study of 69 AEG patients, our results showed that the high expression of MMP-2 was significantly associated with tumor differentiation and depth of invasion (pT). The 5-year survival rate of AEG patients was 40.5%, and it was significantly associated with MMP-2 expression by the univariate analysis. However, MMP-2 expression was not the relevant independent factor for a poor prognosis in multivariate analysis.

Our conclusion was different from Liu X’s. The reason could be attributed to many factors which could affect the experimental results. For example, the techniques used to detect MMP-2 expression might be one important reason for potential bias. Although IHC was the most frequent technique used in clinical research, the results of IHC depend on the primary antibody. Differences in antibody, antibody dilution, and cut-off of defining the specimens as MMP-2 positivity could result in potential heterogeneity. Unfortunately, up to now, there was no common threshold in defining MMP-2 positive expression in AEG patients. It is very important to set a standard threshold in assessment of biomarkers, such as MMP-2, to make the best evaluation of their real function in clinical practices. In order to become a useful prognostic factor at the level of individual patients, our conclusion needs to be further confirmed by an adequately designed prospective research. Moreover, the exact MMP-2 expression value should be determined by both univariate and multivariate analysis in light of the well-established prognostic factors for AEG.

VEGF is an angiogenic factor, which could promote endothelial cells proliferation and migration, enhance blood vessels permeability, and reduce apoptosis of endothelial cells [28,29]. VEGF is correlated with invasion and metastasis in many kinds of cancers, including esophageal and gastric cancer [30,31]. However, few studies have explored the clinical features of VEGF in AEG patients. Gray et al. [32] detected VEGF expression using IHC in tumors specimens from 61 esophagogastric patients. They found that VEGF was overexpressed in tumor
epithelial cells. However, it had no prognostic value for esophagogastric cancer patients. Park et al. [33] also detected VEGF expression in serum levels of ligands from 147 patients who underwent potentially curative resection for gastric and esophagogastric adenocarcinoma. They found that VEGF levels were higher in patients with R1 vs R0 resections. The increased VEGF levels were correlated with decreased overall survival rate. Moreover, the serum VEGF was found as a significantly independent prognostic factor for overall survival. The controversy of the above findings could be possibly due to the different tissue specimens used and different stage or analytic method employed. Even using the same analytic method, the result may differ depending on the site selected for assessment. In our study, the VEGF protein expression in all the patients was detected by IHC. Our data showed that the high expression of VEGF was associated with both tumor depth of invasion (pT) and lymph node metastasis (pN). The 5-year survival rate of AEG patients was associated with VEGF expression by univariate analysis. To eliminate the impact of mixed factors on statistical analysis, we used multivariate analysis to determine prognostic factors, and our result showed that tumor differentiation and pN were relevant independent factors for a poor prognosis.

Recently, some reports showed there was a relationship between VEGF and MMPs in tumor progression. Zhang et al. [34] found that in vitro induction and activity of MMP-2 stimulated by VEGF might be the main mechanism by which VEGF gave impetus to ovarian cancer cells invasion. Wang et al. [35] confirmed that anti-basic fibroblast growth factor (anti-bFGF)-induced invasion of human lung cancer cells could be rescued by inhibiting the AKT/MMP-2/VEGF loop. Partyka et al. [36] confirmed that there was a significantly positive correlation between VEGF and MMP-2 in gastric cancer tissue of patients with metastases. So far, the correlation between VEGF and MMPs in AEG has not been reported in PubMed. In our study, 69.6% AEG cases had high MMP-2 expressions, 71.0% AEG with high VEGF expression, and 56.5% AEG cases had both high expressions of VEGF and MMP-2. Our study showed that MMP-2 expression was positively related to VEGF expression in AEG tissues. We concluded that MMP-2 and VEGF could work synergistically in AEG development.

This is the first report to study the relationship between VEGF and MMP-2 in AEG at clinical level. In our study, all the patients successfully underwent radical operation with regional lymph node dissection. The tumor did not invade other organs, and both edges of resection were confirmed to be free of residual cancer cells by routine histological examination, to ensure complete resection. To eliminate the impact of mixed factors correlated with prognosis on statistical analysis, the Cox regression multivariate analysis was performed to determine the independent prognostic factors. As a result, the comparability was increased and statistical bias was decreased, making the results of this study more objective.

However, the present study still has several limitations. First, in China the indications for treatment not only depend on doctors’ preferences, but also patients’ willingness and economic status. These factors may have influenced the relatively poor survival result observed. In the study, 32 patients received postoperative chemotherapy, 3 patients received postoperative radiotherapy, and 19 patients received combined chemoradiotherapy. However, no statistically significant correlations with
postoperative chemotherapy and radiotherapy were demonstrated for the 5-year survival rate either in univariate or multivariate analysis. Second, this is a retrospective study with a small sample size, which could limit the value of the findings. A randomized-controlled prospective study with a larger sample size will be considered in further investigations.

In conclusion, high MMP-2 expression was significantly associated with tumor differentiation and depth of invasion in AEG patients. In addition, the high expression of VEGF was significantly associated with tumor depth of invasion and lymph node metastasis. There was a positive correlation between MMP-2 and VEGF expressions. Collectively, the results suggest that MMP-2 and VEGF could work synergistically in AEG development.

**Funding information:** This study was supported by the Shandong Provincial Natural Science Foundation (grant no. ZR2020MH204), the 19th batch of science and technology innovation development plan of Jinan in 2020 (Clinical medicine science and technology innovation plan, grant no. 202019032), and the second group of science and technology projects of Jinan Health Committee (grant no. 2020-3-15). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Author contributions:** SZG conceived and supervised the study; ZQK and ZN designed and performed experiments; YQ analyzed data; ZQK and YQ wrote the manuscript; and SZG and ZN revised the manuscript. All the authors read and approved the final version of the manuscript.

**Conflict of interest:** The authors declare that they have no conflicts of interest.

**Data availability statement:** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**References**

[1] Hatta W, Tong D, Lee YY, Ichihara S, Uedo N, Gotoda T. Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. Dig Endosc. 2017;29(Suppl 2):18–25. doi: 10.1111/den.12808.

[2] Liu K, Yang K, Zhang W, Chen X, Chen X, Zhang B, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988–2012: a single-institution, high-volume experience in China. Ann Surg. 2016;263:88–95. doi: 10.1097/SLA.0000000000001168.

[3] Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9. doi: 10.1046/j.1365-2168.1998.00940.x.

[4] Hosoda K, Yamashita K, Katada N, Watanabe M. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. Gen Thorac Cardiovasc Surg. 2015;63:549–56. doi: 10.1007/s11748-015-0575-2.

[5] Huang Q. Carcinoma of the gastroesophageal junction in Chinese patients. World J Gastroenterol. 2012;18:7134–40. doi: 10.3748/wjg.v18.i48.7134.

[6] Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer. 2010;13:63–73. doi: 10.1007/s10120-010-0555-2.

[7] Zhang H, Wang W, Cheng Y, Song Y, Zhu K, Dang C. Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China. World J Surg Oncol. 2013;11:155. doi: 10.1186/1477-7819-11-155.

[8] Roviello G, Petrioli R, Marano L, Polom K, Marrelli D, Perrella A, et al. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer. 2016;19:31–41. doi: 10.1007/s10120-015-0537-5.

[9] Fuchs CS, Niedzwicki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, et al. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance). J Clin Oncol. 2017;35:3671–7. doi: 10.1200/JCO.2017.74.2130.

[10] Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74. doi: 10.1038/nrc745.

[11] Rak B, Mehlich D, Garbicz F, Domosud Z, Paskal W, Marczewska JM, et al. Post-transcriptional regulation of MMP16 and TIMP2 expression via miR-382, miR-410 and miR-200b in endometrial cancer. Cancer Genomics Proteomics. 2017;14:389–401. doi: 10.21873/cgp.200469.

[12] Peng J, Shao N, Peng H, Chen LQ. Prognostic significance of vascular endothelial growth factor expression in esophageal carcinoma: a meta-analysis. J BUON. 2013;18:398–406. doi: 10.1016/j.jpr.2006.12.002.

[13] Honkavuori-Toivola M, Santala M, Soini Y, Turpeenniemi-Hujanen T, Talvensaari-Mattila A. Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma. Dis Markers. 2013;35:261–6. doi: 10.1155/2013/416870.

[14] Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol. 2015;93:18–27. doi: 10.1016/j.critrevonc.2014.05.012.

[15] Shao JB, Li Z, Zhang N, Yang F, Gao W, Sun ZG. Hypoxia-inducible factor-1α in combination with vascular endothelial growth factor could predict the prognosis of postoperative patients with oesophageal squamous cell cancer. Pol J Pathol. 2019;70:84–90. doi: 10.5114/pjp.2019.87100.

[16] Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY, Gao DM. Gene expression profiling of fixed tissues identified hypoxia-
inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res. 2011;17:5463–72. doi: 10.1158/1078-0432.

[17] Berk V, Deniz K, Bozkurt O, Ozaslan E, Karaca H, Inanc M, et al. Predictive significance of VEGF and HIF-1α expression in patients with metastatic colorectal cancer receiving chemotherapy combinations with bevacizumab. Asian Pac J Cancer Prev. 2015;16:6149–54. doi: 10.7314/apjcp.2015.16.14.6149.

[18] Siqueira AS, Carvalho MR, Monteiro AC, Freitas VM, Jaeger RG, Pinheiro JJ. Matrix metalloproteinases, TIMPs and growth factors regulating ameloblastoma behaviour. Histopathology. 2010;57:128–37. doi: 10.1111/j.1365-2559.2010.03596.x.

[19] Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res. 2004;64:652–8. doi: 10.1158/0008-5472.can-0384-2.

[20] Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006;12:1707–14. doi: 10.1158/1078-0432.CCR-05-2338.

[21] Kallakury BV, Karikehalli S, Haholu A, Mueller P, Lopez A, Landen CN, et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113–9. doi: 10.1093/carcin/22.10.1727.

[22] Trudel D, Fradet Y, Meyer F, Harel F, Tétreau B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 2003;63:8511–5.

[23] Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004;10:7621–8. doi: 10.1158/1078-0432.CCR-04-1061.

[24] Shen W, Xi H, Wei B, Chen B, Lin C. The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. J Cancer Res Clin Oncol. 2014;140:1003–9. doi: 10.1007/s00432-014-1630-6.

[25] Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, et al. The role of matrix metalloproteinase 2 in the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010;28:661–9. doi: 10.3109/07357901003735634.

[26] Liu C, Li Y, Hu S, Chen Y, Gao L, Liu D, et al. Clinical significance of matrix metalloproteinase-2 in endometrial cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e10994. doi: 10.1097/MD.0000000000010994.

[27] Lu X, Duan L, Xie H, Lu X, Lu D, Lu D, et al. Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction. Onco Targets Ther. 2016;9:4343–9. doi: 10.2147/OTT.S99580.

[28] Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol. 2015;93:38–27. doi: 10.1016/j.critrevonc.2014.05.012.

[29] Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004;87:95–104. doi: 10.1002/jso.20070.

[30] Peng J, Shao N, Peng H, Chen LQ. Prognostic significance of vascular endothelial growth factor expression in esophageal carcinoma: a meta-analysis. J BUON. 2013;18:398–406. doi: 10.4161/onco.23973.

[31] Liu L, Ma XL, Xiao ZL, Li M, Cheng SH, Wei YQ. Prognostic value of vascular endothelial growth factor expression in resected gastric carcinoma. Asian Pac J Cancer Prev. 2012;13:3089–97. doi: 10.7314/apjcp.2012.13.7.3089.

[32] Gray RT, O’Donnell ME, Maxwell P, McGuigan JA, Spence GM. Long-term follow-up of immunocytochemical analysis of vascular endothelial growth factor (VEGF), and its two receptors, VEGF-R1 (Flt-1) and VEGF-R2 (Flk-1/KDR), in oesophageogastric cancer. Int J Biol Markers. 2013;28:63–70. doi: 10.5301/JBM.2012.10433.

[33] Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, et al. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Ann Surg Oncol. 2014;21:1130–7. doi: 10.1245/s10434-013-3429-0.

[34] Zhang A, Meng L, Wang Q, Xi L, Chen G, Wang S, et al. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol Rep. 2006;15:831–6. doi: 10.3892/or.15.4.831.

[35] Wang Z, Xu H, Zhang J, Jin H, Wei P. Basic fibroblast growth factor blockade enhances lung cancer cell invasion by activating the AKT/MMP-2/VEGF pathway. Basic Clin Pharmacol Toxicol. 2019;17:43–50. doi: 10.1111/bcpt.13290.

[36] Parteya R, Gonciarz M, Jolowiecki P, Förster S, Hark K, Green JE, et al. VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue. Med Sci Monit. 2012;18:BR130–4. doi: 10.12659/MSM.882614.